Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00965484 · ClinicalTrials.gov registry record · Phase 3

Genotropin Study Assessing Use of Injection Pen

A Phase 3 study of Growth Hormone Deficiency and Idiopathic Short Stature, sponsored by Pfizer.

Completed
Registry status
Phase 3
Development phase
136
Enrollment target
20
Study locations

NCT00965484 is a Phase 3 study of Growth Hormone Deficiency and Idiopathic Short Stature that has completed, run by Pfizer. The registered enrollment target is 136 participants, below the 379-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (64% lower). The trial reports 20 study locations across 12 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00965484, a Phase 3 study of Growth Hormone Deficiency and Idiopathic Short Stature, has completed, sponsored by Pfizer.

COMPLETED
Registry status
Phase 3
Development phase
136 participants
Enrollment target
20
Study locations

Study Summary

Assessment of Genotropin patient and caregiver (Dyad) perception of convenience and preference of Genotropin injection pen. Patients already on genotropin will be asked to use a genotropin pen for 2 months. Patient and caregiver will be asked to complete a questionnaire at baseline and 2 months.

Conditions Studied

Growth Hormone Deficiency Idiopathic Short Stature

Interventions

  • DEVICE New Genotropin Pen

Study Locations (20)

Florida

  • Pfizer Investigational Site - Gainesville
  • Pfizer Investigational Site - Gainesville
  • Pfizer Investigational Site - Tallahassee

California

  • Pfizer Investigational Site - Los Angeles
  • Pfizer Investigational Site - San Diego

Maryland

  • Pfizer Investigational Site - Baltimore
  • Pfizer Investigational Site - Baltimore

Ohio

  • Pfizer Investigational Site - Akron
  • Pfizer Investigational Site - Columbus

Pennsylvania

  • Pfizer Investigational Site - Philadelphia
  • Pfizer Investigational Site - Pittsburgh

South Carolina

  • Pfizer Investigational Site - Charleston
  • Pfizer Investigational Site - Florence

Tennessee

  • Pfizer Investigational Site - Memphis
  • Pfizer Investigational Site - Memphis

Colorado

  • Pfizer Investigational Site - Greenwood Village

Trial Details

FieldValue
Enrollment Target 136 participants
Start Date 2009-10
Est. Completion 2010-01
Phase Phase 3

Sponsor

Pfizer

1,845 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT00965484

The ClinicalTrials.gov registry entry for NCT00965484 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 379-participant average among 16 other Growth Hormone Deficiency trials with a reported enrollment target (64% lower). The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.

The record links to 2 conditions, with Growth Hormone Deficiency appearing as the primary indexed condition, and to 1 intervention - of which New Genotropin Pen is the first listed.

NCT00965484 reports 20 study locations spanning 12 distinct geographic areas - top geographies include Florida, California, Maryland.

Frequently Asked Questions

What is clinical trial NCT00965484 about?

NCT00965484 is a clinical study titled "Genotropin Study Assessing Use of Injection Pen". Assessment of Genotropin patient and caregiver (Dyad) perception of convenience and preference of Genotropin injection pen. Patients already on genotropin will be asked to use a genotropin pen for 2 months. Patient and caregiver will be asked to complete a questionnaire at baseline and 2 months.

What is the current status of trial NCT00965484?

This trial is currently completed. It is a Phase 3 study. The enrollment target is 136 participants. The study started on 2009-10. Estimated completion is 2010-01.

What conditions does trial NCT00965484 study?

This clinical trial studies the following conditions: Growth Hormone Deficiency, Idiopathic Short Stature.

What interventions are being tested in trial NCT00965484?

The interventions under investigation include: New Genotropin Pen (DEVICE).

Who is sponsoring clinical trial NCT00965484?

This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00965484 being conducted?

This trial has 20 study locations across California, Colorado, Florida, Indiana, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Growth Hormone Deficiency

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Growth Hormone Deficiency

All registered trials for this condition

Idiopathic Short Stature

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.